Report
Hyloris Pharma - First patient enrolled in Ph2 for bladder pain syndrome
Hyloris announced that they have enrolled the 1st patient in a 4-arm Ph2 study, sponsored by Vaneltix, with Alenura for bladder pain syndrome/interstitial cystitis (PBS/IC).The primary endpoint will be to evaluate the change in Sum of bladder Pain Intensity Differences from baseline to 12 hours (SPID-12) after administration of Alenura vs. its individual active components (lidocaine and heparin), and to placebo as determined by using the 11-point NRS (numerical rating scale) for bladder pain. No impact on investment case and rating as we already anticipated launch of this study in '23: buy. This year, we primarily look forward to October
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
David Seynnaeve, PhD
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.